Literature DB >> 17555804

Identification of platelet hyper-reactivity measured with a portable device immediately after percutaneous coronary intervention predicts in stent thrombosis.

Gianetti Jacopo1, Volpi Elisabetta, Sbrana Silverio, Mariani Massimiliano, Berti Sergio, Andreassi Maria Grazia, Collet Jean Philippe.   

Abstract

INTRODUCTION: Platelet hyper-reactivity, despite a standard anti-thrombotic therapy, is a recognized risk factor for recurrent myocardial ischemia and in-stent thrombosis following PCI. We have investigated whether this detrimental condition, measured by collagen-epinephrine closure times (CEPI-CT) with the Platelet Function Analyzer (PFA-100) device could predict IST defined as the composite of cardiovascular death or myocardial infarction.
MATERIALS AND METHODS: CEPI-CT was measured in 256 consecutive patients with stable angina (n=103) or ACS (n=153) 30+/-8 h after PCI (T 0) and 1 month later (T1). All patients were followed up for a mean period of 9 months. Platelet hyperactivity was defined as a CEPI-CT<190 s.
RESULTS: Baseline CEPI-CT<190 s was associated with a higher rate of death or MI (LogRank chi2=4.23, p=0.039) as compared with CEPI-CT>190 s (4.6% vs. 0.7%). Multivariable analysis after adjustment for other risk factors confirmed that baseline CEPI-CT<190 s was an independent correlate for death or MI (Hazard ratio 6.981, p=0.008). At T1 there was a significant prolongation of CEPI-CT (p=0.03) from 208+/-64 s to 240+/-59 s but T1 did not predict any event.
CONCLUSIONS: A CEPI-CT<190 s measured within the first 24 h following PCI predicts IST defined as the occurrence of death or MI.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17555804     DOI: 10.1016/j.thromres.2007.04.009

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  1 in total

Review 1.  Assessment of platelet inhibition by point-of-care testing in neuroendovascular procedures.

Authors:  H M Hussein; T Emiru; A L Georgiadis; A I Qureshi
Journal:  AJNR Am J Neuroradiol       Date:  2012-03-15       Impact factor: 3.825

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.